Principles of applied pharmacokinetic-pharmacodynamic modeling

Fundamentals of Antimicrobial Pharmacokinetics and Pharmacodynamics

Volumn , Issue , 2014, Pages 63-79

  Wu, Benjamin ^a   Sy, Sherwin K B ^b   Derendorf, Hartmut ^b  

^a AMGEN INC   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

Anti infective; Anti microbial; Concentration dependent; Kill curve; MIC; Pharmacodynamic indices; PKPD modeling and simulation; Time dependent

Indexed keywords

EID: 84926405917     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-75613-4_4     Document Type: Chapter

References (44)

1. Ambrose PG, Bhavnani SM, Rubino C.M., Louie A., Gumbo T, Forrest A, Drusano G.L. (2007) Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin Infect Dis 44(1):79-86
2. Balaban NQ, Merrin J, Chait R., Kowalik L, Leibler S. (2004) Bacterial persistence as a phenotypic switch. Science 305 (5690):1622-1625
3. Barbour A, Schmidt S, Rand K.H., Derendorf H. (2009a) Ceftobiprole: a novel cephalosporin with activity against Gram-positive and Gram-negative pathogens, including methicillin-resistant Staphylococcus aureus (MRSA). Int J Antimicrob Agents 34(1):1-7
4. Barbour A, Schmidt S, Sabarinath S.N., Grant M., Seubert C, Skee D et al (2009b) Soft-tissue penetration of ceftobiprole in healthy volunteers determined by in vivo microdialysis. Antimicrob Agents Chemother 53(7):2773-2776
5. Bulitta JB, Ly NS, Yang J.C., Forrest A., Jusko WJ, Tsuji B.T. (2009) Development and qualification of a pharmacodynamic model for the pronounced inoculum effect of ceftazidime against Pseudomonas aeruginosa. Antimicrob Agents Chemother 53(1):46-56
6. Bulitta JB, Yang JC, Yohonn L, Ly N.S., Brown S V, D'Hondt RE et al (2010) Attenuation of colistin bactericidal activity by high inoculum of Pseudomonas aeruginosa characterized by a new mechanism-based population pharmacodynamic model. Antimicrob Agents Chemother 54(5): 2051-2062
7. Campion JJ, McNamara PJ, Evans M.E. (2004) Evolution of ciprofloxacin-resistant Staphylococcus aureus in in vitro pharmacokinetic environments. Antimicrob Agents Chemother 48(12): 4733-4744
8. Craig WA (1998) Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 26(1):1-10, quiz 11-12
9. Craig WA, Redington J, Ebert S.C. (1991) Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections. J Antimicrob Chemother 27(Suppl C):29-40
10. Czock D, Keller F. (2007) Mechanism-based pharmacokinetic-pharmacodynamic modeling of antimicrobial drug effects. J Pharmacokinet Pharmacodyn 34(6):727-751
11. Dasgupta A (2007) Usefulness of monitoring free (unbound) concentrations of therapeutic drugs in patient management. Clin Chim Acta 377(1-2):1-13
12. de la Pena A, Grabe A, Rand KH, Rehak E, Gross J, Thyroff-Friesinger U et al (2004) PK-PD modelling of the effect of cefaclor on four different bacterial strains. Int J Antimicrob Agents 23(3):218-225
13. Drusano GL (1990) Human pharmacodynamics of beta-lactams, aminoglycosides and their combination. Scand J Infect Dis Suppl 74:235-248
14. Drusano GL, D'Argenio DZ, Preston SL, Barone C, Symonds W., LaFon S et al (2000) Use of drug effect interaction modeling with Monte Carlo simulation to examine the impact of dosing interval on the projected antiviral activity of the combination of abacavir and amprenavir. Antimicrob Agents Chemother 44(6):1655-1659
15. Garrett ER, Nolte H. (1972) Kinetics and mechanisms of drug action on microorganisms. XIV. The action of fluorouracil, other uracils and derived nucleosides on the microbial kinetics of Escherichia coli. Chemotherapy 17(2):81-108
16. Garrett ER, Miller GH, Brown M.R. (1966) Kinetics and mechanisms of action of antibiotics on microorganisms. V. Chloramphenicol and tetracycline affected Escherichia coli generation rates. J Pharm Sci 55(6):593-600
17. Gershenfeld NA (1999) The nature of mathematical modeling. Cambridge University Press, Cambridge
18. Grasso S, Meinardi G, de Carneri I, Tamassia V. (1978) New in vitro model to study the effect of antibiotic concentration and rate of elimination on antibacterial activity. Antimicrob Agents Chemother 13(4):570-576
19. Hoffman A, Stepensky D. (1999) Pharmacodynamic aspects of modes of drug administration for optimization of drug therapy. Crit Rev Ther Drug Carrier Syst 16(6):571-639
20. Jumbe N, Louie A, Leary R., Liu W, Deziel MR, Tam VH et al (2003) Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy. J Clin Invest 112(2):275-285
21. Leggett JE, Fantin B, Ebert S., Totsuka K, Vogelman B, Calame W et al (1989) Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thighinfection models. J Infect Dis 159(2):281-292
22. Liu P, Rand KH, Obermann B, Derendorf H. (2005) Pharmacokinetic-pharmacodynamic modelling of antibacterial activity of cefpodoxime and cefixime in in vitro kinetic models. Int J Antimicrob Agents 25(2):120-129
23. Mielck JB, Garrett E.R. (1969) Kinetics and mechanisms of drug action on microorganisms. IX. Inhibitory action of lincomycin on Escherichia coli by microbial kinetics. Chemotherapy 14(6):337-355
24. Mohamed AF, Nielsen EI, Cars O, Friberg L.E. (2012) Pharmacokinetic-pharmacodynamic model for gentamicin and its adaptive resistance with predictions of dosing schedules in newborn infants. Antimicrob Agents Chemother 56(1):179-188
25. Moise PA, Schentag J.J. (1998) Pharmacokinetic and pharmacodynamic modelling of antibiotic therapy. Curr Opin Infect Dis 11(6):673-680
26. Mouton JW, Vinks A.A. (2005) Pharmacokinetic/pharmacodynamic modelling of antibacterials in vitro and in vivo using bacterial growth and kill kinetics: the minimum inhibitory concentration versus stationary concentration. Clin Pharmacokinet 44(2):201-210
27. Mouton JW, Vinks AA, Punt N.C. (1997) Pharmacokinetic-pharmacodynamic modeling of activity of ceftazidime during continuous and intermittent infusion. Antimicrob Agents Chemother 41(4):733-738
28. Mouton JW, Theuretzbacher U, Craig W.A., Tulkens PM, Derendorf H, Cars O. (2008) Tissue concentrations: do we ever learn? J Antimicrob Chemother 61(2):235-237
29. Mueller M, de la Pena A, Derendorf H (2004) Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC. Antimicrob Agents Chemother 48(2):369-377
30. Nielsen EI, Viberg A, Lowdin E., Cars O, Karlsson MO, Sandstrom M. (2007) Semimechanistic pharmacokinetic/pharmacodynamic model for assessment of activity of antibacterial agents from time-kill curve experiments. Antimicrob Agents Chemother 51(1):128-136
31. Owens RC J.r., Bhavnani SM, Ambrose P.G. (2005) Assessment of pharmacokinetic-pharmacodynamic target attainment of gemifloxacin against Streptococcus pneumoniae. Diagn Microbiol Infect Dis 51(1):45-49
32. Sanfilippo A, Morvillo E. (1968) An experimental model for the study of the antibacterial activity of the sulfonamides. Chemotherapy 13(1):54-60
33. Sanfilippo A, Schioppacassi G. (1973) New approach to the evaluation of antibacterial activity of aminosidine. Chemotherapy 18(5):297-303
34. Schmidt S, Barbour A, Sahre M., Rand KH, Derendorf H. (2008) PK/PD: new insights for antibacterial and antiviral applications. Curr Opin Pharmacol 8(5):549-556
35. Schmidt S, Sabarinath SN, Barbour A, Abbanat D., Manitpisitkul P, Sha S et al (2009) Pharmacokinetic-pharmacodynamic modeling of the in vitro activities of oxazolidinone antimicrobial agents against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 53(12):5039-5045
36. Schuck EL, Derendorf H. (2005) Pharmacokinetic/pharmacodynamic evaluation of anti-infective agents. Expert Rev Anti Infect Ther 3(3):361-373
37. Tam VH, Ledesma KR, Vo G, Kabbara S., Lim TP, Nikolaou M. (2008) Pharmacodynamic modeling of aminoglycosides against Pseudomonas aeruginosa and Acinetobacter baumannii: identifying dosing regimens to suppress resistance development. Antimicrob Agents Chemother 52(11):3987-3993
38. Treyaprasert W, Schmidt S, Rand K.H., Suvanakoot U., Derendorf H. (2007) Pharmacokinetic/pharmacodynamic modeling of in vitro activity of azithromycin against four different bacterial strains. Int J Antimicrob Agents 29(3):263-270
39. Tsuji BT, Brown T, Parasrampuria R., Brazeau DA, Forrest A, Kelchlin PA et al (2012a) Frontloaded linezolid regimens result in increased killing and suppression of the accessory gene regulator system of Staphylococcus aureus. Antimicrob Agents Chemother 56(7):3712-3719
40. Tsuji BT, Bulitta JB, Brown T, Forrest A., Kelchlin PA, Holden PN et al (2012b) Pharmacodynamics of early, high-dose linezolid against vancomycin-resistant enterococci with elevated MICs and pre-existing genetic mutations. J Antimicrob Chemother 67(9):2182-2190
41. Turnidge JD (1998) The pharmacodynamics of beta-lactams. Clin Infect Dis 27(1):10-22
42. Vogelman B, Gudmundsson S, Leggett J., Turnidge J, Ebert S, Craig W.A. (1988) Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J Infect Dis 158(4):831-847
43. Wu B, Derendorf H. (2010) Pharmacokinetic/pharmacodynamic model-based combination therapy approach to target antibiotic resistant populations emerged from ciprofloxacin exposure. Pharmazie 65(6):417-420
44. Yano Y, Oguma T, Nagata H., Sasaki S. (1998) Application of logistic growth model to pharmacodynamic analysis of in vitro bactericidal kinetics. J Pharm Sci 87(10):1177-1183